Cardiomyopathies and Arrhythmias Induced by Cancer Therapies

Emerging paradigms in cardiomyopathies associated with cancer therapies.

The cardiovascular care of cancer patients (cardio-oncology) has emerged as a new discipline in clinical medicine, given recent advances in cancer therapy, and is driven by the cardiovascular complications that occur as a direct result of cancer therapy. Traditional therapies such as anthracyclines and radiation have been recognized for years to have cardiovascular complications. Less expected ...

Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies

Objectives There is little information about arrhythmia burden in cancer survivors with chemotherapy-induced cardiomyopathy (CIC). We hypothesise that the rates and risk of arrhythmias will be similar in CIC when compared with other non-ischaemic cardiomyopathy (NICMO) aetiologies. Methods We retrospectively identified nine patients with CIC and an implantable defibrillator and 18 age and sex...

Therapies for ventricular cardiac arrhythmias.

During recent years, engineers and physicists have become increasingly interested in studying the electrical activity of the heart. Despite the fact that the heart is a complex and highly nonlinear system, its electrical behavior can be studied using a variety of experimental and clinical techniques, and can be modeled mathematically using relatively simple systems of differential equations, al...

Drug-Induced Cardiomyopathies

Heart failure represents one of most important causes of death in Western countries. Its high mortality originates in part from severe complications like cardiac contractile dysfunction and/or sudden cardiac death caused by ventricular arrhythmias (Shin et al. 2007). Unfortunately, significant portion of heart failure stems from use (and misuse) of several drugs and medications. Indeed, the car...

Advances in nonpharmacologic therapies for ventricular arrhythmias